doi: 10.5732/cjc.012.10098

The genetics and biology of KRAS in lung cancer

Peter M. K. Westcott, Minh D. To

Pharmaceutical Sciences and Pharmacogenomics Program, Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA

[Abstract] Mutational activation of KRAS is a common oncogenic event in lung cancer and other epithelial cancer types. Efforts to develop therapies that counteract the oncogenic effects of mutant KRAS have been largely unsuccessful, and cancers driven by mutant KRAS remain among the most refractory to available treatments. Studies undertaken over the past decades have produced a wealth of information regarding the clinical relevance of KRAS mutations in lung cancer. Mutant Kras-driven mouse models of cancer, together with cellular and molecular studies, have provided a deeper appreciation for the complex functions of KRAS in tumorigenesis. However, a much more thorough understanding of these complexities is needed before clinically effective therapies targeting mutant KRAS-driven cancers can be achieved.

Chinese Journal of Cancer 2013, Volume: 32, Issue 2, Page: 63-70

[ PDF Full-text ]
[ Html full-text ](PubMed Central)
[ PubMed ]
[Google Scholar]

Cite this article

Peter M. K. Westcott, Minh D. To. The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2013, 32(2):63-70. doi:10.5732/cjc.012.10098


Export citations

EndNote